Streetbeat News

Earnings

MOR

MorphoSys shares continue to decline after the company released trial results. The specific details of the trial results, such as the nature of the trial, the data outcomes, or the market's reaction, are not provided in the article.

Portfolio Pulse from Charles Gross

November 20, 2023 | 10:03 pm

KEYS

Keysight Technologies (NYSE:KEYS) reported Q4 earnings of $1.99 per share, surpassing estimates of $1.87, despite a 7.01% decrease from the previous year. Revenue was $1.31 billion, slightly above the $1.30 billion estimate but down 9.22% from last year. The company's cash flow from operations was $378 million, and free cash flow remained steady at $340 million. KEYS provided Q1 guidance with earnings between $1.53 and $1.59 per share, below the $1.67 estimate, and revenue projections between $1.235 billion and $1.255 billion, around the $1.24 billion estimate. After the report, KEYS shares rose 1.67% to $137.21 in after-hours trading.

Portfolio Pulse from Ryan Gustafson

November 20, 2023 | 9:50 pm

CNTB

Connect Biopharma Holdings Limited (NASDAQ:CNTB) will release long-term data from its China pivotal trial of rademikibart for moderate-to-severe atopic dermatitis on November 21, 2023. The announcement will be followed by a conference call and webcast presentation to discuss the results.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:42 pm

CNET

ZW Data Action Technologies reported a Q3 2023 EPS of $(0.21), an improvement from $(0.40) YoY. Revenue increased to $9.181M from $7.216M YoY.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:36 pm

CENTA

Central Garden & Pet (NASDAQ:CENTA) reported Q4 earnings with an EPS of $0.1, surpassing the estimate of $0.07 by 42.86%. Revenue increased by $42.70 million compared to the same period last year. Despite beating EPS estimates last quarter, the share price dropped by 0.3% the following day. The company's past earnings performance shows a mixed track record of beating and missing EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:35 pm

MOR

MorphoSys announced positive results from its Phase 3 MANIFEST-2 study of Pelabresib in Myelofibrosis, meeting the primary endpoint with a significant improvement in spleen volume reduction (SVR35) and showing a strong positive trend in symptom reduction for the overall population and significant improvements for intermediate-risk patients.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:31 pm

BYU

CISS

GFAI

HRT

JAN

NCNC

PEGY

PMEC

RCRT

SGBX

SYM

VINO

In Monday's after-market session, Symbotic (SYM) saw a significant increase of 19.7% in stock price after Q4 earnings release. Other gainers included Primech Holdings (PMEC), noco-noco (NCNC), Recruiter.Com Group (RCRT), JanOne (JAN), and Safe & Green Holdings (SGBX), with various percentage increases. On the losing side, Gaucho Group Holdings (VINO), Guardforce AI Co (GFAI), C3is (CISS), HireRight Holdings (HRT), Baiyu Holdings (BYU), and Pineapple Energy (PEGY) experienced declines in their stock prices.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:31 pm

AKTS

ARQQ

CISO

EGIO

FEIM

GVP

MARK

OBLG

PRST

QBTS

QMCO

SMRT

In Monday's after-market session, several IT stocks experienced significant movements. GSE Systems (GVP) saw a 9.7% increase after their Q3 earnings report 4 days ago. Akoustis Technologies (AKTS) rose by 7.38%, while Frequency Electronics (FEIM) increased by 6.88%. Edgio (EGIO) also gained 4.99% post their Q3 earnings report. SmartRent (SMRT) and D-Wave Quantum (QBTS) saw modest gains. Conversely, Presto Automation (PRST) dropped by 8.9% after their Q1 earnings report, Remark Holdings (MARK) fell by 4.35%, Oblong (OBLG) by 3.96%, Arqit Quantum (ARQQ) by 3.63%, CISO Global (CISO) by 3.5%, and Quantum (QMCO) by 2.77%.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:31 pm

XELB

Xcel Brands (NASDAQ:XELB) reported Q3 earnings with an EPS of $-0.15, beating estimates by 6.25% but with a revenue decrease of $1.86 million YoY. Last quarter's EPS beat led to a 5.13% share price increase the following day. Historical earnings performance shows variability in meeting EPS estimates.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:30 pm

RCEL

AVITA Medical's stock is trading lower following the company's announcement of reduced revenue guidance for FY23, which is below market expectations.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:29 pm